Karyopharm Therapeutics (KPTI) Raw Materials (2019 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Raw Materials came in at $628000.0 in Q4 2025, down 12.78% YoY from $720000.0 in Q4 2024, and little changed on a QoQ basis from $630000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Raw Materials (2019 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 7 years of Raw Materials data on file, last reported at $628000.0 in Q4 2025.
- Quarterly Raw Materials fell 12.78% year-over-year to $628000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $628000.0 (down 12.78% YoY) and the FY2025 annual result came in at $628000.0, down 12.78% from the prior year.
- Raw Materials steadied at $628000.0 in Q4 2025, from $630000.0 in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $2.6 million in Q1 2022 to a low of $261000.0 in Q2 2022.
- A 5-year average of $1.0 million and a median of $720000.0 in 2024 frame the typical range for Raw Materials.
- Annual changes were most pronounced in 2022 — Raw Materials tumbled 85.7% — and 2023, when it surged 330.65%.
- Tracing KPTI's Raw Materials over 5 years: stood at $1.8 million in 2021, then declined by 23.76% to $1.4 million in 2022, then tumbled by 59.64% to $553000.0 in 2023, then surged by 30.2% to $720000.0 in 2024, then slipped by 12.78% to $628000.0 in 2025.
- The last three Raw Materials figures came in at $628000.0 (Q4 2025), $630000.0 (Q3 2025), and $477000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - |
| 10 | Karyopharm Therapeutics | 55.27 Mn | 55.27 Mn | 32.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 628,000.00 |
| Dec 31, 2025 | 628,000.00 |
| Sep 30, 2025 | 630,000.00 |
| Jun 30, 2025 | 477,000.00 |
| Mar 31, 2025 | 508,000.00 |
| Dec 31, 2024 | 720,000.00 |
| Sep 30, 2024 | 720,000.00 |
| Jun 30, 2024 | 723,000.00 |
| Mar 31, 2024 | 553,000.00 |
| Dec 31, 2023 | 553,000.00 |
| Sep 30, 2023 | 391,000.00 |
| Jun 30, 2023 | 1.12 Mn |
| Mar 31, 2023 | 1.12 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | 262,000.00 |
| Jun 30, 2022 | 261,000.00 |
| Mar 31, 2022 | 2.56 Mn |
| Dec 31, 2021 | 1.80 Mn |
| Sep 30, 2021 | 1.71 Mn |
| Jun 30, 2021 | 1.83 Mn |